Physician profile
Edward Friedman
NPI 1659558260
$7,991.42
in general payments reported to CMS, 2019-2025
37 companies · $1,426 in 2025
The $1,426 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,391 · 2020: $278 · 2021: $244 · 2022: $1,333 · 2023: $1,339 · 2024: $1,980 · 2025: $1,426.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,745.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,744.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,244.57 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $962.63 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Gilead Sciences, INC. | $625.89 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $495.27 | 2019-2025 | Entyvio, Gattex |
| Allergan, INC. | $276.89 | 2019 | |
| Ironwood Pharmaceuticals, INC | $270.75 | 2020-2025 | Linzess |
| Celgene Corporation | $263.13 | 2021-2024 | Zeposia |
| Genzyme Corporation | $259.40 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $250.33 | 2022-2025 | Dupixent |
| Intercept Pharmaceuticals, INC. | $180.95 | 2022-2025 | Ocaliva |
| Olympus America INC. | $178.59 | 2019-2020 | |
| Boston Scientific Corporation | $176.90 | 2019-2025 | Exalt Model D |
| Janssen Biotech, INC. | $150.37 | 2022-2025 | Tremfya, Stelara |
| Ardelyx, INC. | $143.26 | 2023-2025 | Ibsrela |
| Pfizer INC. | $133.94 | 2019-2025 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $130.42 | 2024 | Terlivaz |
| Lilly USA, LLC | $129.65 | 2024-2025 | Omvoh, Zepbound |
| Merck Sharp & Dohme LLC | $125.89 | 2023-2024 | Dificid |
| Nestle Healthcare Nutrition INC. | $125.11 | 2022-2023 | |
| Qol Medical, LLC | $122.39 | 2022-2024 | Sucraid |
| Madrigal Pharmaceuticals | $116.01 | 2024-2025 | Rezdiffra, Resmetirom |
| Phathom Pharmaceuticals, INC. | $103.20 | 2024-2025 | Voquezna |
| Aimmune Therapeutics, INC. | $95.25 | 2024-2025 | Vowst, Zenpep |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.38 | 2023-2024 | Cyltezo |
| Organon LLC | $57.92 | 2022-2024 | |
| Fresenius Kabi USA, LLC | $47.23 | 2023-2024 | Idacio |
| Amgen INC. | $47.02 | 2021-2023 | Avsola, Amjevita |
| Ipsen Biopharmaceuticals, INC | $38.15 | 2024-2025 | Iqirvo, Bylvay |
| Enterra Medical, INC. | $33.14 | 2023-2025 | |
| Ucb, INC. | $28.56 | 2019 | |
| Evoke Pharma, INC. | $27.44 | 2022 | |
| Shield Therapeutics INC | $17.12 | 2023 | Accrufer |
| Novo Nordisk INC | $16.42 | 2025 | Wegovy |
| Celltrion USA INC. | $14.10 | 2025 | Vegzelma |
| Redhill Biopharma INC. | $13.72 | 2022 | |
| Braintree Laboratories, INC. | $13.54 | 2024 | Suflave, Sutab |
| Ferring Pharmaceuticals INC. | $12.89 | 2023 | Rebyota |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Friedman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.